CBIO Stock Summary and Trading Ideas (Crescent Biopharma | NASDAQ:CBIO)

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Crescent Biopharma trades on the NASDAQ stock market under the symbol CBIO.

As of April 10, 2026, CBIO stock price declined to $18.17 with 153,255 million shares trading.

CBIO has a beta of 1.30, meaning it tends to be more sensitive to market movements. CBIO has a correlation of 0.03 to the broad based SPY ETF.

CBIO has a market cap of $553.22 million. This is considered a Small Cap stock.

Last quarter Crescent Biopharma reported $11 million in Revenue and -$4.01 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$1.43.

The top ETF exchange traded funds that CBIO belongs to (by Net Assets): VTI, VXF, AVSC.

CBIO support price is $17.77 and resistance is $20.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CBIO shares will trade within this expected range on the day.